Private Placement

Kane Biotech (TSX‑V: KNE) announced a non‑brokered private placement of up to 16 million common shares at $0.05 each, seeking up to $800,000 in gross proceeds. Funds will support working capital and general corporate needs, including its revyve® wound‑care platform. Insiders may participate. Closing is expected around December 17 2025, subject to TSX Venture Exchange approval, and all shares will be subject to a four‑month‑plus‑one‑day lock‑up. The offering is not registered in the United States and cannot be sold to U.S. persons.

dynaCERT Inc. announced a non‑brokered private placement of up to $2 million in convertible unsecured units, each containing a 5%‑interest note maturing in two years (convertible into 13,333,333 shares at $0.15) and 6,666,667 warrants exercisable at $0.20 for two years. Proceeds will fund global expansion of HydraGEN™ emissions‑reduction technology, working capital, and corporate initiatives. Units are offered to qualified investors under Canadian and applicable offshore exemptions, with a four‑month lock‑up. Concurrently, director Jean‑Pierre Colin resigned after nine years.

NV Gold (NVGLF / TSXV:NVX) closed a shares-for-debt deal and the final tranche of a private placement, raising about C$666,199. Proceeds will fund exploration at the Slumber Gold Project and bolster working capital. The offering included units with warrants exercisable at C$0.40. The company issued 1,310,384 shares for debt settlement, potentially diluting shareholder value. Securities are subject to a hold period and TSXV approval. The financing aims to advance exploration and unlock the potential of the Slumber Gold Project.

Gold Terra (YGTFF) has increased its non-brokered private placement to C$7M due to strong investor demand, issuing 55M common shares. The offering includes common, charitable flow-through, and flow-through shares. Proceeds will fund qualifying Canadian exploration expenses by December 31, 2026, with renouncement by December 31, 2025. Closing is expected around November 28, 2025, pending TSX Venture Exchange approval. Finder’s fees amount to C$28,000, and securities are subject to a four-month hold.

Carpenter Technology (NYSE: CRS) plans a private placement of $700 million in senior notes due 2034, targeting qualified institutional buyers and select non-U.S. investors. Net proceeds, combined with cash, will redeem 6.375% notes due 2028 and repay 7.625% notes due 2030, with remaining funds for general corporate purposes. The offering is subject to market conditions. The notes are not registered under the Securities Act. This announcement is not a redemption notice.

Questcorp Mining (QQCMF) closed the first tranche of a private placement on Oct 24, 2025, raising $2.1M by issuing 14M+ units priced at $0.15. Each unit includes a share and a half warrant, exercisable at $0.20 until Oct 24, 2027. $2M is subject to a Sharing Agreement with Sorbie Bornholm LP, settled in 24 monthly tranches based on a 20-day VWAP benchmarked against $0.1949. This could result in variable monthly proceeds.

Nevada Sunrise (NVSGF) closed a $650,000 private placement, issuing 13,000,000 units at $0.05 each, comprised of a share and a warrant. Due to investor demand, the offering was upsized from $600,000. Net proceeds will fund Nevada exploration, property investigations, and working capital. Securities are subject to a hold until March 7, 2026. Canaccord Genuity received cash and finder’s warrants. The offering awaits TSX Venture Exchange acceptance and is not registered in the U.S.

NV Gold (NVGLF) closed the first tranche of a private placement, raising $616,199 for exploration at the Slumber Gold Project. The offering consisted of 3,423,330 Units at $0.18, each including a share and a warrant exercisable at $0.40. Insiders subscribed for 3,190,000 Units, increasing John Watson’s stake to 58.65%. Proceeds will fund exploration and working capital. Securities are subject to a four-month hold. TSXV approval is required.

VIQ Solutions (VQSSF) closed the second tranche of an upsized private placement on November 5, 2025, raising approximately C$585,000. The company issued 3,146,063 units at C$0.186 per unit, each including a share and a warrant exercisable at C$0.190 until 2030. Total proceeds from the placement exceed C$3.0 million. Proceeds will fund technology innovations, organic growth, acquisitions, and restructuring. The issuance of new units will cause some share dilution.

Hemostemix (HMTXF) closed the first tranche of a private placement, raising $461,230 by issuing 4,193,000 Units at $0.11 each. Each Unit includes a share and a warrant exercisable at $0.15. Proceeds fund working capital and VesCell marketing. Finder’s fees were paid, and certain directors participated, triggering related party considerations with MI 61-101 exemptions. The closing is subject to regulatory approval, and securities are subject to a four-month hold period. The offering introduces potential dilution from new shares and warrants.